On September 2, 2020, Santhera announced their new licensing agreement with ReveraGen Pharma, the company up until now, responsible for vamorolone. This agreement offers Santhera the advantage of full control of vamorolone. It allows them to pursue the development, registration, and commercialization of this anti-inflammatory drug candidate more effectively and efficiently.
Santhera remains committed to moving the vamorolone program forward in the most expeditious way possible and continues to keep our community informed on any new updates or developments.
Defeat Duchenne Canada has been a partner with ReveraGen, having funded $1 million towards their VBP15-006 clinical trial program in Canada evaluating vamorolone in very young children aged 2-4 and older boys aged 7-18.
We are very excited about what this new agreement with Santhera might bring to our Canadian community. We will continue to update you on this program.
If you have any questions regarding this information or the vamorolone clinical trial program, please contact:
Director of Research and Advocacy
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs.